Early Detection Reimagined
No needles, no mess, no stress — and no waiting. Our saliva screening in the time it takes to sip a drink.
Learn MoreThe Problem
The screening barrier is the sample itself
Blood draws require needles and medical settings. Stool tests create discomfort and compliance barriers. Both make regular screening harder than it should be.
How it Works
Collect saliva
A noninvasive saliva sample begins the screening workflow.
Isolate exosomes
The sample is processed to separate extracellular vesicles that may contain tumor-derived material.
Expose DNA cargo
Exosomes are opened so the assay can access DNA associated with the target signal.
Amplify NANOGP8
PCR is used to amplify the NANOGP8-associated sequence, including the reported 22 bp insertion in the 3′-UTR region.
Read the signal
A detected signal suggests NANOGP8 is present and should be followed by diagnostic evaluation.
Why NANOG
- NANOG/NANOGP8 is linked in the literature to cancer stemness, tumor progression, and aggressive disease biology.
- Sugaya-related work studied exosomal NANOG DNA and NANOGP8-associated sequences as potential diagnostic biomarkers.
- The assay is investigational and intended to flag a signal for follow-up evaluation, not replace definitive diagnosis.
The reasons this changes everything you know about early testing
Saliva-Based Collection
Only 2 mL saliva required—no needles, no stool handling, no clinic visits. Designed for maximum patient comfort and compliance.
Broad Cancer Ambition
Expanding validation across multiple cancer types beyond initial patent samples, with commercial launch phase now active.
Beats Mammography*
Mammograms have high false-positives (up to 50%), miss dense breasts, raise anxiety. Saliva NANOGP8 offers non-invasive, accurate alternative without radiation.(No testing vs mammograms has been done or is planned).
Standard PCR Workflow
Integrates with existing molecular lab infrastructure for scalable processing—no specialized equipment required.
Early Detection Edge
NANOGP8 in saliva exosomes flags cancers early (e.g., breast, prostate). Displaces poor prognostic imaging for proactive screening.
A dramatically simpler experience
Saliva NANOG DNA
2 mL saliva sample
No needles – At-home collection
No stool handling
Stool Tests
Stool collection / handling
Compliance friction
Embarrassment factor
Messy process
Blood Tests
Venipuncture required
Clinic / lab visit
Needle phobia barrier
Repeat discomfort
Imaging-Based Biopsies
Mammography / Low-Dose CT
Radiologic scanning or guided biopsy
Equipment-intensive
Radiation exposure
- 2 mL saliva sample
- No needles
- No stool handling
- Standard PCR
A simpler sample in a market worth billions
Built on peer-reviewed science
Exosomal NANOG DNA
NANOG/NANOGP8 linked to cancer stemness, tumor progression, and aggressive biology across multiple cancers. Exosomal DNA carries tumor-specific signals.
Patent-Protected
US Patent covers exosomal NANOG DNA methodology. Platform protected for commercial development and scalability.
Peer-Reviewed Foundation
Sugaya et al. (PLoS ONE 2023) research on glioblastoma-derived exosomes.
Peer-Reviewed Journal Articles
Commercial Launch Phase Active
April 7, 2026: NexTel Medical announces first commercial milestone—test kit distribution has begun for control sample collection to validate against 100 dedicated test samples.
- Control samples now being collected
- 100 dedicated test samples for validation
- Expanding across broader cancer types
- Patent-protected platform advancing to market
Ready to participate?
Clinics, labs, and research partners: Join the validation network.
Partner With Us
The future of screening
may start with saliva
Be among the first to access NexTel’s NANOG DNA platform.
Sign Up FreeCancer Testing
For Research Use Only
